BMY - Bristol-Myers Squibb Company
| Previous Close | 66.78 |
| Open | 66.75 |
| Bid | 66.76 x 900 |
| Ask | 66.99 x 800 |
| Day's Range | 66.70 - 67.21 |
| 52 Week Range | 42.48 - 67.21 |
| Volume | 14,374,964 |
| Avg. Volume | 18,685,082 |
| Market Cap | 156.404B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | 19.28 |
| EPS (TTM) | 3.46 |
| Earnings Date | Feb 05, 2020 |
| Forward Dividend & Yield | 1.80 (2.70%) |
| Ex-Dividend Date | Dec 31, 2019 |
| 1y Target Est | 70.60 |
- Benzinga
9 Takeaways From The JPMorgan Healthcare Conference
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...
- Zacks
Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now?
Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.
- Zacks
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
- MoneyShow
Top Picks 2020- Bristol-Myers Squibb BMY
With politicians on both sides of the aisle calling for drug price controls, and a number of the Democratic candidates calling for "Medicare for all," it has been a challenging environment for a host of medical sectors, suggests income expert Chuck Carlson, editor of DRIP Investor.
- Zacks
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
- Zacks
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy
- Zacks
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
- Benzinga
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15) 10X Genomics Inc (NASDAQ: TXG ) Aimmune Therapeutics ...
- Zacks
Nektar's Pain Drug Gets Adverse Advisory Committee Decision
Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.
- Zacks
Snap Up These 5 Stocks With High Earnings Yield
Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed-income securities.
- Zacks
Top Ranked Income Stocks to Buy for January 15th
Top Ranked Income Stocks to Buy for January 15th
- Zacks
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
- Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
U.S. FDA Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer
- Moody's
Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Biogen Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Barrons.com
Big Merger Deals Are Missing at Health Conference. Here’s Why.
What a difference a year makes. The start of the annual J.P. Morgan Healthcare investor conference in 2019 brought a double-header of giant deals. In 2020, there was almost nothing.
- Zacks
Top Ranked Income Stocks to Buy for January 14th
Top Ranked Income Stocks to Buy for January 14th
- Zacks
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $66.15, marking a +1.41% move from the previous day.
- American City Business Journals
In time for biotech's biggest conference, Union Square costs climb
Joe Panetta knows that Union Square is the place where he has to be during the week of the J.P. Morgan Healthcare Conference, which starts Monday. Hotel rooms, many used exclusively for meetings, cost as much as $1,000 a night as 20,000-plus drug company, venture capital and investment banking personnel swarm Union Square. Any space is at a premium — reflected in the $300 price last year to sit at a table in the lobby of the Sir Francis Drake Hotel for three hours.
- Zacks
The Extreme Risks of Trading Your Own Retirement Assets - January 13, 2020
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
- Zacks
Retirees Should Know These 3 Facts About Required Minimum Distributions - January 13, 2020
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
- Zacks
Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration
Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Investor's Business Daily
Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing
Pharma giant Bristol-Myers Squibb deepened its cancer treatment partnership with Nektar Therapeutics on Friday — leading NKTR stock to pop to its highest point since August 2019.
- Zacks
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
- TheStreet.com
Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer
Nektar Therapeutics shares leap as the company and Bristol-Myers said they would expand their partnership to develop a cancer treatment.
